简达生物医药

Janda Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of novel small molecule drugs for oncology and metabolic disorders. The company utilizes a sophisticated structure-based drug design (SBDD) platform to identify and optimize inhibitors for high-value targets, particularly within the ubiquitin-proteasome system and DNA damage repair pathways. Its lead candidate is a potent and selective USP1 inhibitor designed to treat cancers with specific genetic vulnerabilities through synthetic lethality. Janda Biotech is backed by prominent venture capital firms and led by a team of experienced industry veterans from global pharmaceutical organizations. The company's research strategy focuses on addressing unmet medical needs by targeting proteins previously considered difficult to drug.